Related Experiment Video
Updated: Jul 19, 2025
05:35
Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
Published on: June 6, 2025
255
Contrast-enhanced mammography-guided biopsy: technique and initial outcomes.
Ya-Chun Tang1,2, Yun-Chung Cheung1,2
1Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Linkou Center, Taoyuan.
Quantitative Imaging in Medicine and Surgery
|August 15, 2023
Summary
Contrast-enhanced mammography-guided biopsy (CEM-Bx) is a new, highly successful technique for diagnosing enhanced breast lesions. This study shows CEM-Bx is feasible and effective, achieving a 100% biopsy success rate.
Area of Science:
- Radiology
- Oncology
- Medical Imaging
Background:
- Contrast-enhanced mammography-guided biopsy (CEM-Bx) is a novel diagnostic technique commercialized in 2021.
- Limited existing literature documents the procedural performance and outcomes of CEM-Bx.
Purpose of the Study:
- To evaluate the procedural performance and preliminary outcomes of CEM-Bx.
- To assess the feasibility and diagnostic yield of CEM-Bx in a clinical setting.
Main Methods:
- A retrospective review of 12 women who underwent CEM-Bx between September 2021 and June 2022.
- Data collected included demographic and procedural characteristics, biopsy success rate, histopathological diagnosis, and average glandular dose (AGD).
Main Results:
- CEM-Bx demonstrated a 100% success rate in diagnosing enhanced breast lesions.
- The malignancy rate was 66.7%, with both vertical and horizontal needle approaches proving effective.
- The mean procedure time was 17±6.3 minutes, and the mean AGD was 14.3±12.3 mGy.
Conclusions:
- CEM-Bx is a feasible and effective technique for diagnosing contrast-enhanced breast lesions.
- The high success rate and diagnostic yield support the clinical utility of CEM-Bx.
